MCID: CHL066
MIFTS: 52

Cholangitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis 12 28 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9446
ICD10 32 K83.0
ICD9CM 34 576.1
MeSH 41 D002761
NCIt 46 C26718
UMLS 69 C0008311

Summaries for Cholangitis

Disease Ontology : 12 A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary : Cholangitis is related to sclerosing cholangitis, neonatal and suppurative cholangitis. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Allograft rejection and Influenza A. The drugs Ciprofloxacin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Acute Cholangitis Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 34.1 CFTR CLDN1 DCDC2
2 suppurative cholangitis 33.1 ABCB4 CRP DLAT TNF
3 cholangitis, primary sclerosing 33.0 ABCB4 CFTR DLAT FUT2 GGT1 GPBAR1
4 cholecystitis 32.2 ABCB4 ALB F2 GPT
5 sclerosing cholangitis 31.8 ABCB4 ALB CD40LG CFTR CLDN1 DCDC2
6 hepatitis 30.8 CLDN1 F2 GGT1 GPT TNF
7 autoimmune pancreatitis 30.7 CA2 CFTR HLA-DRB1 TNF
8 choledocholithiasis 30.5 ABCB4 ALB F2 GPT
9 cholelithiasis 30.2 ABCB4 ALB GPT
10 cholestasis 30.1 ABCB4 F2 GGT1 GPT
11 primary biliary cirrhosis 30.1 ABCB4 ALB CA2 CD40LG DLAT F2
12 pure red-cell aplasia 30.0 ALB HLA-B HLA-DRB1
13 portal hypertension 29.9 ALB F2 GPT TNF
14 liver cirrhosis 29.9 ALB F2 GGT1 GPT
15 inflammatory bowel disease 29.8 ALB CRP HLA-B HLA-DRB1 IL6 TNF
16 hepatitis a 29.8 ALB F2 GPT TNF
17 autoimmune hepatitis 29.6 CD40LG DLAT F2 GGT1 GPT HLA-DRB1
18 psoriatic arthritis 29.6 CRP HLA-B HLA-DRB1 TNF
19 hepatitis c 29.6 CLDN1 GGT1 GPT TNF
20 intrahepatic cholestasis 29.5 ABCB4 ALB GGT1 GPBAR1
21 hepatitis b 29.5 ALB F2 GGT1 GPT TNF
22 fatty liver disease 29.5 GGT1 GPT IL6 TNF
23 biliary tract disease 29.4 ABCB4 ALB F2 GGT1 GPBAR1
24 cystitis 29.3 CRP IL6 TNF
25 bile duct disease 29.3 ABCB4 ALB F2 GGT1 GPBAR1 GPT
26 obstructive jaundice 29.3 ALB F2 GGT1 GPBAR1 GPT IL6
27 acute pyelonephritis 29.3 ALB CRP IL6
28 liver disease 29.2 ABCB4 ALB DLAT F2 GGT1 GPT
29 gastroenteritis 29.1 ALB CRP FUT2 IL6 TNF
30 autoimmune disease 29.1 CD40LG HLA-B HLA-DRB1 IL6 TNF
31 pyelonephritis 29.0 ALB CRP IL6 TNF
32 granulomatous hepatitis 29.0 CD40LG CRP GGT1
33 bacterial meningitis 29.0 ALB CRP IL6 TNF
34 kawasaki disease 29.0 ALB CRP IL6 TNF
35 sickle cell anemia 28.9 CD40LG F2 TNF
36 body mass index quantitative trait locus 11 28.9 CRP GGT1 GPT IL6 TNF
37 acalculous cholecystitis 28.9 CD40LG CRP
38 intussusception 28.9 CD40LG CFTR CRP IL6
39 bronchiolitis 28.8 CD40LG IL6 TNF
40 peritonitis 28.7 ALB CRP F2 IL6 TNF
41 acquired immunodeficiency syndrome 28.6 ALB CD40LG HLA-B IL6 TNF
42 pneumonia 28.6 CD40LG CRP IL6 TNF
43 osteoporosis 28.3 ALB CA2 CRP IL6 TNF
44 meningitis 28.1 ALB CD40LG CRP IL6 TNF
45 leptospirosis 28.0 CD40LG CRP F2 IL6 TNF
46 rheumatoid arthritis 27.9 CD40LG CRP HLA-B HLA-DRB1 IL6 TNF
47 systemic lupus erythematosus 27.5 ALB CD40LG CRP F2 HLA-DRB1 IL6
48 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.4
49 ascending cholangitis 12.4
50 secondary sclerosing cholangitis 12.3

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Acute Pancreatitis
Biliary Tract Neoplasm Cholecystitis
Cholestasis Deficiency Anemia
Familial Atrial Fibrillation Gallbladder Cancer
Heart Disease Hepatitis
Intrahepatic Gall Duct Cancer Pancreatic Cancer
Pancreatitis, Hereditary Paralytic Ileus
Postcholecystectomy Syndrome Primary Biliary Cirrhosis
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:



Diseases related to Cholangitis

Symptoms & Phenotypes for Cholangitis

MGI Mouse Phenotypes related to Cholangitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 ABCB4 IL6 ALB TNF CA2 CFTR
2 endocrine/exocrine gland MP:0005379 9.81 GGT1 GPBAR1 ABCB4 IL6 ALB TNF
3 immune system MP:0005387 9.7 GPBAR1 ABCB4 IL6 TNF CA2 CD40LG
4 reproductive system MP:0005389 9.28 GGT1 ABCB4 IL6 TNF CA2 CD40LG

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Azithromycin Approved Phase 4 83905-01-5 53477736 447043 55185
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
4
Vancomycin Approved Phase 4,Phase 3,Phase 1 1404-90-6 14969 441141
5
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
6
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
7
Cefoxitin Approved Phase 4 35607-66-0 441199
8
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128-13-2 31401
9
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
10
Metronidazole Approved Phase 4,Phase 1 443-48-1 4173
11
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18 Temocillin Approved, Investigational Phase 4 66148-78-5
19 Clavulanic Acid Phase 4
20 Amoxicillin-Potassium Clavulanate Combination Phase 4
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 4,Phase 2
24 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
25 Antitubercular Agents Phase 4
26 glucocorticoids Phase 4,Phase 1
27 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Topoisomerase Inhibitors Phase 4,Phase 2
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Hormone Antagonists Phase 4,Phase 1
32 Hormones Phase 4,Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
34 Immunoglobulins Phase 4,Phase 2,Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
37 Antibodies Phase 4,Phase 2,Phase 1
38 Antiprotozoal Agents Phase 4,Phase 1
39 Antiparasitic Agents Phase 4,Phase 1
40 Bile Acids and Salts Phase 4,Phase 2,Phase 1
41 Antirheumatic Agents Phase 4,Phase 1,Phase 2
42 Prednisolone acetate Phase 4
43 Cathartics Phase 4,Phase 3
44 Renal Agents Phase 4
45 Methylprednisolone acetate Phase 4
46 Methylprednisolone Hemisuccinate Phase 4
47 Prednisolone hemisuccinate Phase 4
48 Prednisolone phosphate Phase 4
49 Laxatives Phase 4,Phase 3
50 Antineoplastic Agents, Hormonal Phase 4

Interventional clinical trials:

(show top 50) (show all 186)

# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Unknown status NCT02057679 Phase 4 Amoxicillin clavulanic;Placebo
3 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
4 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
6 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
7 Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction Completed NCT02909595 Phase 4
8 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
9 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
10 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
11 Leflunomide for Maintenance of Remission in IgG4 Related Disease Recruiting NCT02703194 Phase 4 Prednisone;Leflunomide
12 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
13 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Not yet recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
14 Temocillin Pharmacokinetics in Paediatrics Not yet recruiting NCT02260102 Phase 4 Temocillin
15 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
16 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
17 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
18 Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones Unknown status NCT01425177 Phase 3
19 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
20 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
21 Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 2, Phase 3 Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
22 The Effect of Bezafibrate on Cholestatic Itch Recruiting NCT02701166 Phase 3 Bezafibrate;Placebo
23 Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Recruiting NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
24 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
25 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Active, not recruiting NCT01802073 Phase 3 Oral Vancomycin
26 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Active, not recruiting NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
27 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
28 Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice Unknown status NCT01275768 Phase 1, Phase 2
29 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
30 Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP Completed NCT02098486 Phase 2 Moxifloxacin;ceftriaxone
31 Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
32 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
33 Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
34 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
35 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
36 Rituximab in IgG4-RD: A Phase 1-2 Trial Completed NCT01584388 Phase 1, Phase 2 Rituximab
37 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Recruiting NCT03394924 Phase 2 EDP-305 Dose 1;EDP-305 Dose 2;Placebo
38 Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Recruiting NCT01688024 Phase 2 Mitomycin C;Normal saline
39 Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid Recruiting NCT03092765 Phase 2 E6011;Placebo
40 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Recruiting NCT02239211 Phase 2 BTT1023
41 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Recruiting NCT02978339 Phase 1, Phase 2 Curcumin
42 A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Recruiting NCT03394781 Phase 2 DUR-928
43 Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis Recruiting NCT03155932 Phase 2 APD334
44 Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis Recruiting NCT02943447 Phase 2 GS-9674;Placebo to match GS-9674
45 An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis Recruiting NCT03359174 Phase 2 All-trans retinoic acid
46 Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid Recruiting NCT03124108 Phase 2 Elafibranor 80 mg;Elafibranor 120 mg;Placebo
47 A Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS) Recruiting NCT03112681 Phase 2 Saroglitazar magnesium 2 mg;Saroglitazar magnesium 4 mg;Placebo Oral Tablet
48 A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of LJN452 in PBC Patients Recruiting NCT02516605 Phase 2 LJN452;Placebo
49 Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT02955602 Phase 2 MBX-8025 2 mg Capsule;MBX-8025 5 mg Capsule;MBX-8025 10 mg Capsule
50 A POC and Dose-Ranging Study of HTD1801 in PSC Patients Recruiting NCT03333928 Phase 2 HTD1801;Placebo

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Genetic Tests for Cholangitis

Genetic tests related to Cholangitis:

# Genetic test Affiliating Genes
1 Cholangitis 28

Anatomical Context for Cholangitis

MalaCards organs/tissues related to Cholangitis:

38
Liver, T Cells, Colon, Neutrophil, Testes, Thyroid, B Cells

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 1710)
# Title Authors Year
1
Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis. ( 29414663 )
2018
2
Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. ( 29380060 )
2018
3
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
4
Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). ( 29032610 )
2018
5
Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis. ( 29401491 )
2018
6
The significance of serum IgG<sub>4</sub>and CA19-9, autoantibodies in diagnosis and differential diagnosis of IgG<sub>4</sub>-related sclerosing cholangitis. ( 29272982 )
2018
7
Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. ( 29405510 )
2018
8
Environmental basis of primary biliary cholangitis. ( 29307284 )
2018
9
Re: Cholangitis 3 years after laparoscopic cholecystectomy. ( 29392901 )
2018
10
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. ( 29378311 )
2018
11
Quality of life and primary sclerosing cholangitis: the business of defining what counts. ( 29315689 )
2018
12
Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. ( 29321484 )
2018
13
Clinical applicability of Tokyo guidelines 2018/2013 in diagnosis and severity evaluation of acute cholangitis and determination of a new severity model. ( 29374984 )
2018
14
Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis. ( 29443746 )
2018
15
Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis. ( 29314124 )
2018
16
Risk factor analysis of post-ERCP cholangitis: A single-center experience. ( 29428105 )
2018
17
Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. ( 29090868 )
2018
18
Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. ( 29313399 )
2018
19
Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. ( 29411404 )
2018
20
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
21
Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis. ( 29333790 )
2018
22
Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication. ( 29278002 )
2018
23
Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients with Primary Biliary Cholangitis. ( 29427734 )
2018
24
Lack of Correlation of Liver Tests With Fibrosis Stage at Diagnosis in Pediatric Primary Sclerosing Cholangitis. ( 29356767 )
2018
25
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. ( 29301479 )
2018
26
Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes. ( 29331078 )
2018
27
A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis? ( 29316057 )
2018
28
Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. ( 29320524 )
2018
29
Primary Biliary Cholangitis in British Columbia First Nations: Clinical features and discovery of novel genetic susceptibility loci. ( 29297981 )
2018
30
The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7. ( 29429758 )
2018
31
Mucinous cystic neoplasm of the liver with extrahepatic growth presenting with ascending cholangitis diagnosed by endoscopic ultrasound features: a case report. ( 29444709 )
2018
32
Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314130 )
2018
33
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
34
Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice. ( 29449577 )
2018
35
Primary Biliary Cholangitis-A Autoimmune Hepatitis Overlap Syndrome. ( 29423670 )
2018
36
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
37
Shorter Duration of Antibiotic Treatment for Acute Bacteraemic Cholangitis with Successful Biliary Drainage:A Retrospective Cohort Study. ( 29408612 )
2018
38
Successful treatment of<i>Providencia rettgeri</i>cholecystitis and neutrophilic cholangitis in a cat. ( 29399368 )
2018
39
Peribiliary Cysts presenting as Primary Sclerosing Cholangitis. ( 29432923 )
2018
40
Re: Acute cholangitis: current concepts. ( 29392900 )
2018
41
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
42
Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. ( 29090866 )
2018
43
Outcomes Associated With Timing of ERCP in Acute Cholangitis Secondary to Choledocholithiasis. ( 29356786 )
2018
44
Rituximab therapy in rheumatoid arthritis and primary biliary cholangitis. ( 29338925 )
2018
45
Endoscopic diagnosis and treatment of biliary obstruction due to acute cholangitis and acute pancreatitis secondary to Fasciola hepatica infection. ( 29350372 )
2018
46
Tokyo Guidelines 2018: updated Tokyo Guidelines for the management of acute cholangitis/acute cholecystitis. ( 29334699 )
2018
47
Persistent reduction of mucosal-associated invariant T cells in primary biliary cholangitis. ( 29266628 )
2017
48
Indications and techniques of biliary drainage for acute cholangitis in updated Tokyo guidelines 2018. ( 28834389 )
2017
49
Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. ( 28839442 )
2017
50
Novel CLDN1 mutation in ichthyosis-hypotrichosis-sclerosing-cholangitis syndrome without signs of liver disease. ( 28906553 )
2017

Variations for Cholangitis

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Pathways for Cholangitis

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 ALB CA2 CD40LG CRP F2 GGT1
2 external side of plasma membrane GO:0009897 9.46 CD40LG F2 HLA-DRB1 TNF
3 extracellular exosome GO:0070062 9.4 ABCB4 ALB CA2 CEACAM5 CFTR CRP

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.77 CD40LG HLA-B HLA-DRB1 IL6 TNF
2 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-B HLA-DRB1 SP100
3 response to dexamethasone GO:0071548 9.4 ABCB4 CLDN1
4 positive regulation of STAT protein import into nucleus GO:2000366 9.26 F2 IL6
5 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
6 acute-phase response GO:0006953 9.13 CRP F2 IL6
7 negative regulation of lipid storage GO:0010888 8.8 CRP IL6 TNF

Sources for Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....